Table 1 Demographic and clinical variables at the time of the BAL

From: HHV-6B detection and host gene expression implicate HHV-6B as pulmonary pathogen after hematopoietic cell transplant

 

Negative HHV-6B

DNA in BAL (N = 71)

Positive HHV6-B DNA in BAL (any level) (N = 42)a

Positive HHV6-B DNA in BAL ≥ 2.3 log10 copies/mL (N = 27)a

Total (N = 113b)

Age, years

    

<=20

0 (0%)

1 (2%)

1 (4%)

1 (1%)

21–40

17 (24%)

15 (36%)

10 (37%)

32 (28%)

41–60

27 (38%)

10 (24%)

6 (22%)

37 (33%)

>60

27 (38%)

16 (38%)

10 (37%)

43 (38%)

Female sex

27 (38%)

22 (52%)

13 (48%)

49 (43%)

Race

    

Caucasian

53 (75%)

33 (79%)

20 (74%)

86 (76%)

Non-Caucasian

15 (21%)

9 (21%)

7 (26%)

24 (21%)

Unknown

3 (4%)

0 (0%)

0 (0%)

3 (3%)

Year of HCT

    

2015

6 (8%)

0 (0%)

0 (0%)

6 (5%)

2016

12 (17%)

5 (12%)

4 (15%)

17 (15%)

2017

22 (31%)

16 (38%)

11 (41%)

38 (34%)

2018

18 (25%)

7 (17%)

5 (19%)

25 (22%)

2019

13 (18%)

14 (33%)

7 (26%)

27 (24%)

Center

    

City of Hope

20 (28%)

16 (38%)

9 (33%)

36 (32%)

Fred Hutch

46 (65%)

24 (57%)

17 (63%)

70 (62%)

MSKCC

5 (7%)

2 (5%)

1 (4%)

7 (6%)

CMV serostatus

    

D- and R-

10 (14%)

4 (10%)

3 (11%)

14 (12%)

D+ or R+

61 (86%)

36 (86%)

22 (81%)

97 (86%)

Missing

0 (0%)

2 (5%)

2 (7%)

2 (2%)

HCT comorbidity index scorec

    

0 (low)

8 (11%)

3 (7%)

3 (11%)

11 (10%)

1–2 (intermediate)

20 (28%)

11 (26%)

8 (30%)

31 (27%)

>=3 (high)

43 (61%)

28 (67%)

16 (59%)

71 (63%)

HLA D/R status

    

Matched related

9 (13%)

7 (17%)

6 (22%)

16 (14%)

Matched unrelated

26 (37%)

14 (33%)

6 (22%)

40 (35%)

Mismatched related

11 (15%)

8 (19%)

7 (26%)

19 (17%)

Mismatched unrelated

24 (34%)

12 (29%)

7 (26%)

36 (32%)

Missing

1 (1%)

1 (2%)

1 (4%)

2 (2%)

Donor cell source

    

Peripheral blood

51 (72%)

33 (79%)

18 (67%)

84 (74%)

Bone marrow

16 (23%)

7 (17%)

7 (26%)

23 (20%)

Umbilical cord blood

4 (6%)

2 (5%)

2 (7%)

6 (5%)

Myeloablative conditioningd

32 (45%)

14 (33%)

10 (37%)

46 (41%)

Maximum corticosteroid use pre-BALe

    

None

39 (55%)

17 (40%)

11 (41%)

56 (50%)

<1 mg/kg/day

13 (18%)

18 (43%)

12 (44%)

31 (27%)

≥1 mg/kg/day

19 (27%)

7 (17%)

4 (15%)

26 (23%)

Maximum oxygen use pre-BAL > 2 L/minf

30 (42%)

21 (50%)

14 (52%)

51 (45%)

WBC count pre-BALg

    

>1000 cells/mm3

50 (70%)

31 (74%)

7 (26%)

81 (72%)

≤1000 cells/mm3

17 (24%)

10 (24%)

19 (70%)

27 (24%)

Missing

4 (6%)

1 (2%)

1 (4%)

5 (4%)

ALC pre-BALg

    

>300 cells/mm3

27 (38%)

11 (26%)

17 (63%)

38 (34%)

≤300 cells/mm3

33 (46%)

26 (62%)

7 (26%)

59 (52%)

Missing

11 (15%)

5 (12%)

3 (11%)

16 (14%)

ANC pre-BALg

    

>500 cells/mm3

48 (68%)

29 (69%)

17 (63%)

77 (68%)

≤500 cells/mm3

12 (17%)

8 (19%)

7 (26%)

20 (18%)

Missing

11 (15%)

5 (12%)

3 (11%)

16 (14%)

Day of BAL post-HCT (median, IQR)

37 (15-68)

42 (20–79)

31 (20–72)

37 (19–76)

Antiviral therapy at time of sample collectionh

24 (34%)

12 (29%)

6 (22%)

36 (32%)

LRTD causei

    

Bacterial

7 (10%)

3 (7%)

2 (7%)

10 (9%)

Viral

12 (17%)

6 (14%)

3 (11%)

18 (16%)

Fungal

16 (23%)

10 (24%)

8 (30%)

26 (23%)

IPS

14 (20%)

4 (10%)

4 (15%)

18 (16%)

Other

9 (13%)

2 (5%)

0 (0%)

11 (10%)

Multifactorial

13 (18%)

17 (40%)

10 (37%)

30 (27%)

  1. Data are presented as number (percentage), unless otherwise indicated.
  2. HHV-6B human herpesvirus 6B, BAL bronchoalveolar lavage, D donor, R recipient, HLA human leukocyte antigen, D donor, R recipient, WBC white blood cell, ALC absolute lymphocyte count, ANC absolute neutrophil count, LRTD lower respiratory tract disease, IPS idiopathic pneumonia syndrome.
  3. aGroups are not mutually exclusive.
  4. b3 of the 116 enrolled participants did not have a BAL fluid sample available for testing and are excluded from this Table and from the analyses that incorporate BAL fluid HHV-6B test results.
  5. cBased on the HCT-comorbidity index.
  6. dMyeloablative regimens included any regimen containing ≥800 cGY TBI, any regimen containing carmustine/etoposide/cytarabine/melphalan (BEAM), or any regimen containing busulfan/cyclophosphamide with or without antithymocyte globulin.
  7. eWithin 14 days pre-BAL, based on prednisone-equivalent dosing.
  8. fWithin 24 h preceding the BAL.
  9. gClosest sample within 3 days pre-BAL.
  10. hGanciclovir, foscarnet, or cidofovir for CMV or adenovirus.
  11. iAdditional details on specific causes are in Table S1.
Back to article page